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Introduction 
Vaccination against influenza is one of the most effective measures to protect people from 
contracting illness during influenza epidemics and pandemics (1). In Belgium, the Interminis-
terial Influenza Coordination Committee defined three main objectives for the vaccination 
campaign against Influenza A(H1N1)2009 pandemic. The first objective was to maintain the 
functioning of the health care system. The staff in hospitals and health professionals was 
then considered as priority groups for vaccination. This could limit the transmission of the 
infection from professional health workers to patients. The second objective was to limit 
complications and mortality due to influenza. Chronic conditions possibly related to a higher 
rate of complications and mortality have been listed in the literature available at the time. 
Patients suffering from one of those affections, women in their second or third trimester of 
pregnancy and parents of children aged less than six months constituted the second group to 
be vaccinated. The third objective was to maintain the continuity of the educational system 
and avoid an amplifying effect in educational institutions. The school staff was therefore de-
fined as the third group to be vaccinated (1, 4).  
Pandemrix (via a 10 doses phial packaging) was the only vaccine brand selected for the Bel-
gian vaccination campaign. Pandemrix is an adjuvanted inactivated vaccine, containing 
antigens analogous to the A/California/7/2009(H1N1)v virus. The Influenza Scientific Com-
mittee recommended a single dose for persons aged 10 years or older, and two times half a 
dose for children aged 6 months to 9 years (1, 2, 3). 
The vaccination campaign was entrusted to general practitioners and hospitals, and the dis-
tribution of the vaccine was organised through the pharmaceutical network. 
Simultaneously, a secure web-based tool was developed to allow practitioners to record data 
about patients they vaccinated. This recording system combined objectives of pharmacovigi-
lance and evaluation of the vaccination campaign. Post-vaccine complications were recorded 
through a dedicated form used in the pharmacovigilance surveillance system managed by 
the Federal Agency for Medicines and Health Products (FAMHP). Patient data allowed the 
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Scientific Institute of Public Health (WIV-ISP) to describe the geographical and age distribu-
tion of vaccinated persons.  
From 19 October until 6 November, the vaccine was available for hospital health workers 
only. From 7 November, the vaccine was proposed for free to other priority groups previously 
mentioned. The phasing of the vaccine distribution was also related to stock availability.  
This article describes the web-based recording system and gives some results of the data 
collected. 
Material and methods 
The ‘eH1N1 vaccination’ web page was hosted on the eHealth platform which is a public 
portal created to promote and facilitate secure and electronic exchange of health data (5). 
To access or encode data on this platform, an identity card reader, a Belgian electronic iden-
tity card and a PIN code (access code) were required. The ‘eH1N1 vaccination’ web page 
was available for two different groups: for citizens who wanted to check their vaccination 
status and print a vaccination certificate and for practitioners who wanted to check the vacci-
nation status of a patient or record a new vaccination. 
Data required for a new vaccination record were the national number of the patient (NISS 
code), the date of the vaccination and codes of the antigen and the adjuvant batches. No 
data on the risk status of the patient were recorded. For foreign patients without a NISS 
code, personal data (name, first name, birth year and sex) have to be encoded manually to 
print the certificate but these data were not stored in the database. Several control rules were 
installed to reduce coding mistakes to a minimum. Based on the national number, personal 
data of the patient (birth year, gender and postcode) were then extracted from the national 
database. An update of this information was sent by e-mail to the WIV-ISP every day but for 
confidentiality reasons, the national number of the patient was encrypted. These data were 
analysed using Stata 10.1 and a daily report was produced for the public health authorities 
as well as a weekly report for the FAMHP. 
For the pharmacovigilance surveillance, a pandemic dedicated form used to record post-
vaccine adverse reactions was sent to practitioners through a medical newspaper (Folia Par-
macotherapeutica). Patients with complications were welcome to contact their practitioner in 
order to fill out this form. This specific notification form was also accessible via the FAMHP 
website. 
Results 
Number of recorded vaccinations 
Figure 1 shows the daily number of vaccinations recorded through the system and the 
weekly incidence curve of influenza-like illnesses (ILIs) as well as the epidemic threshold.  
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The total number of vaccinations recorded from 19 October 2009 until 31 March 2010 
amounted to 733,025. On a weekly basis, 43% of the total number of vaccinations were re-
corded in week 46 (from 9 to 15 November), two weeks after the epidemic peak.  
After week 46, this number reduced by 50% each week until the end of 2009. In 2010, less 
than 3000 vaccinations were recorded. To give a global idea, health authorities estimated 
that 2,000,000 doses of the vaccine have been distributed during the pandemic period.  
Figure 1. Daily number of vaccinated persons recorded through the system 
 
Vaccination coverage by region 
The number of vaccinations recorded by region showed a big difference between Flanders 
and Wallonia/Brussels. Among all vaccination registrations, 87% occurred in the Flemish 
Region.  
Figure 2 illustrates the cumulative percentage of vaccinations within each Belgian province. 
Flemish provinces (West-Vlaanderen, Oost-Vlaanderen, Antwerpen, Limburg and Vlaams-
Brabant) had a cumulative percentage between 8.7% and 11.3% and the Walloon provinces 
(Hainaut, Namur, Liège, Luxembourg, Brabant wallon) as well as the Brussels-Capital Re-
gion had a cumulative percentage between 1.3% and 1.9%. These differences were due to a 
controversy among French-speaking practitioners. They felt uncomfortable about recording 
their vaccinations mainly for confidentiality reasons. 
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Figure 2. Cumulative percentage of vaccination recorded by Belgian provinces, situation on 31 March 2010 
 
 
Vaccination coverage by age group 
The vaccination coverage among age groups in Table 1 underlines that the elderly are the 
most vaccinated group with a coverage of 17.4% for the 65-84-year-olds and 30.0% for the 
group of people aged 85 years and above. If the coverage is considered only for Flanders 
that has a better reporting, one quarter of the age group 65-84 years is vaccinated and 44% 
of the age group 85 years and more. Children (less than 14 years) are less vaccinated with 
around 1% of vaccination coverage. This situation corresponds to the authorities’ recom-
mendations as the elderly are the group with the highest risk that should be vaccinated due 
to pre-existing chronic pathologies. 
Table 1. Reported vaccination coverage by age group, situation on 31 March 2010 
 Vaccination coverage (%) in 
Age group Belgium Flanders Wallonia Brussels 
0-4 years 0.8 1.1 0.2 0.2 
5-14 years 1.0 1.5 0.3 0.3 
15-64 years 5.3 7.9 1.1 1.4 
65-84 years 17.4 24.9 3.9 5.2 
85 years + 30.0 44.3 7.2 9.8 
TOTAL 6.56 10.2 1.5 1.9 




From 19 October until 15 February 2010, a total of 158 Adverse Drug Reaction (ADRs) re-
ports have been sent to the Belgian Centre of Pharmacovigilance (BCP) of the FAMHP. All 
reports came from Health Care Professionals (physicians / pharmacists) or from GSK, the 
Marketing Authorisation Holder (MAH) of Pandemrix. The most frequently reported ADRs 
were injection site reactions, influenza-like illness including fever and myalgia, allergic reac-
tions (rash, urticaria, bronchospasm, angiooedema and anaphylaxis) and neurological 
reactions (especially paraesthesia and neuritis). All these reactions are mentioned in the 
summary of product characteristics and in the public leaflet of Pandemrix. The BCP also 
registered 6 cases of deaths, related in time to the vaccination. In one case, the patient was 
a 30-year-old man who had a cardiac arrest. In the other cases, the age of the patients was 
between 68 and 90 years. For five of the six cases, important comorbidity confounding fac-
tors such as chronic cardiac and/or respiratory disease could explain the death. In case of 
the 30-year-old man, it was difficult to correctly assess this case in the absence of an au-
topsy. The link with the vaccination could not be ruled out as there is a temporal relation with 
the event. However, sudden deaths may occur in apparent healthy subjects (8, 9). The BCF 
did not receive any case of Guillain-Barré syndrome. The safety profile observed in Belgium 
is in line with the safety data reported at the European level (7).  
A broad evaluation was made of the relative reporting rate in Belgium of the vaccine’s ADRs 
compared to the total reporting rate for all medicinal products. This was done by comparing 
the number of ADR reports received for the pandemic vaccine (during the vaccination cam-
paign) and for all medicinal products (on a yearly basis). The ratio obtained in Belgium was 
28%, compared to 18% in France and 13% in the United Kingdom. We can conclude that the 
relative reporting rate of ADRs for the pandemic vaccines was better in Belgium than in 
France and UK. Nevertheless, this estimation should be cautiously interpreted as the abso-
lute number of ADRs reported, when corrected in function of the population, remains very 
low in Belgium (number of ADR reports per million inhabitants in Belgium: 16.6, in France: 
60.3 and in UK: 52.2). 
Discussion 
Benefits of the system 
This web-based recording system was easily accessible for general practitioners and citizens 
with Internet access and an identity card reader. The limited number of coding fields, the 
data validity control rules and the link with the national database, together with a short en-
coding phase, offer a significant amount of information of quality.  
Information provided by the system was first of all of importance for the authorities to follow 
the vaccination coverage rate in the population. In case of an adverse effect of the vaccine, 
this database can also be very useful to identify vaccinated persons. In the pharmacovigi-
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lance point of view, exposure data are very important in order to make observed versus ex-
pected ADR analyses. Moreover, the age stratification of the exposure data could be useful 
in the context of massive children / elderly patients vaccination. The specific pharmacovigi-
lance reporting system established in Belgium in order to control the safety of the pandemic 
vaccine was a success in view of the total rate of reporting for all medicinal products.  
Weaknesses of the system 
Authorities should improve the communication about the confidentiality of the information and 
should convince people, especially practitioners, of the interest of this kind of tool. This data-
base can be really effective if a maximum of concerned persons would join the project. The 
recording system is still active to allow practitioners to record former vaccinations. 
Without having more information about the proportion of chronic diseases in the different age 
groups, the vaccination coverage for targeted groups is difficult to estimate.  
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